Intravenous Immunoglobulin in Children with Streptococcal Toxic Shock Syndrome
- 1 November 2009
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (9), 1369-1376
- https://doi.org/10.1086/606048
Abstract
Background.Streptococcal toxic shock syndrome (TSS) is a rare and severe manifestation of group A streptococcal infection. The role of intravenous immunoglobulin (IVIG) for streptococcal TSS in children is controversial. This study aims to describe the epidemiology of streptococcal TSS in children and to determine whether adjunctive therapy with IVIG is associated with improved outcomes. Methods.A multicenter, retrospective cohort study of children with streptococcal TSS from 1 January 2003 through 31 December 2007 was conducted. Propensity scores were used to determine each child's likelihood of receiving IVIG. Differences in the primary outcomes of death, hospital length of stay, and total hospital costs were compared after matching IVIG recipients and nonrecipients on propensity score. Results.The median patient age was 8.2 years. IVIG was administered to 84 (44%) of 192 patients. The overall mortality rate was 4.2% (95% confidence interval, 1.8%-8.0%). Differences in mortality between IVIG recipients (n=3; 4.5%) and nonrecipients (n=3; 4.5%) were not statistically significant (P>.99). Although patients receiving IVIG had higher total hospital and drug costs than nonrecipients, differences in hospital costs were not significant once drug costs were removed (median difference between matched patients, $6139; interquartile range, −$8316 to $25,993; P=.06). No differences were found in length of hospital stay between matched IVIG recipients and nonrecipients. Conclusion.This multicenter study is, to our knowledge, the largest to describe the epidemiology and outcomes of children with streptococcal TSS and the first to explore the association between IVIG use and clinical outcomes. IVIG use was associated with increased costs of caring for children with streptococcal TSS but was not associated with improved outcomes.Keywords
This publication has 40 references indexed in Scilit:
- Intravenous Immunoglobulin G Therapy in Streptococcal Toxic Shock Syndrome: A European Randomized, Double-Blind, Placebo-Controlled TrialClinical Infectious Diseases, 2003
- Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity ScoresAnnals of Internal Medicine, 2002
- Invasive Group A Streptococcal Infections: T1M1 Isolates Expressing Pyrogenic Exotoxins A and B in Combination with Selective Lack of Toxin?Neutralizing Antibodies Are Associated with Increased Risk of Streptococcal Toxic Shock SyndromeThe Journal of Infectious Diseases, 1999
- Relation Between Low Capacity Of Human Sera To Inhibit Streptococcal Mitogens And Serious Manifestation Of DiseaseThe Journal of Infectious Diseases, 1994
- Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive Group A streptococcal infections compared with adultsThe Pediatric Infectious Disease Journal, 1994
- Severe Invasive Group A Streptococcal Infections In Ontario, Canada: 1987-1991Clinical Infectious Diseases, 1993
- T cell activation and cytokine release in streptococcal toxic shock-like syndromeThe Journal of Pediatrics, 1993
- Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections.1993
- Aspects of Pathogenesis of Serious Group A Streptococcal Infections in Sweden, 1988-1989The Journal of Infectious Diseases, 1992
- An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction.The Journal of Immunology, 1991